{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["Glioma", "TMZ", "angiopep-2", "radiosensitized polyprodrug", "synergetic therapy"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "30744436", "DateCompleted": {"Year": "2019", "Month": "05", "Day": "10"}, "DateRevised": {"Year": "2020", "Month": "02", "Day": "25"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1080/10717544.2018.1534897"], "Journal": {"ISSN": "1521-0464", "JournalIssue": {"Volume": "26", "Issue": "1", "PubDate": {"Year": "2019", "Month": "Dec"}}, "Title": "Drug delivery", "ISOAbbreviation": "Drug Deliv"}, "ArticleTitle": "Self-assembled angiopep-2 modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles delivery TMZ for glioma synergistic TMZ and RT therapy.", "Pagination": {"StartPage": "34", "EndPage": "44", "MedlinePgn": "34-44"}, "Abstract": {"AbstractText": ["The addition of temozolomide (TMZ) to radiotherapy (RT) improves survival of patients with glioblastoma (GBM). However, TMZ\u2009+\u2009RT causes excess toxicity in patients. In this study, we prepared angiopep-2 (A2) modified lipid-poly (hypoxic radiosensitized polyprodrug) nanoparticles for TMZ delivery (A2-P(MIs)25/TMZ) to achieve synergistic effects against glioma. This A2-P(MIs)25/TMZ display highly promising advantages: (1) a hydrophobic P-(MIs)25 core where poorly water-soluble TMZ can be encapsulated; (2) nitro groups of the hydrophobic P-(MIs)25 core that are converted into hydrophilic amino groups (P(NH<sub>2</sub>s)25) under low oxygen conditions to mimic the oxygen-increased sensitization to RT; (3) a lipid monolayer at the interface of the core and the shell to modify the A2 (a specific ligand for low-density lipoprotein receptor-related protein-1 (LRP-1), which are expressed in the blood-brain barrier (BBB) and human glioma cells), thereby enhancing the drug encapsulation efficiency in glioma. These nanoparticles appear as a promising and robust nanoplatforms for TMZ and hypoxic cell radiosensitization delivery."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Nanjing Medical University , Nanjing , China."}, {"Identifier": [], "Affiliation": "b Institute of Nervous System Diseases , Xuzhou Medical University , Xuzhou , China."}, {"Identifier": [], "Affiliation": "c Department of Neurosurgery , Affiliated Hospital of Xuzhou Medical University , Xuzhou , China."}], "LastName": "Zong", "ForeName": "Zhenkun", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Nanjing Medical University , Nanjing , China."}, {"Identifier": [], "Affiliation": "b Institute of Nervous System Diseases , Xuzhou Medical University , Xuzhou , China."}, {"Identifier": [], "Affiliation": "c Department of Neurosurgery , Affiliated Hospital of Xuzhou Medical University , Xuzhou , China."}], "LastName": "Hua", "ForeName": "Lei", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "b Institute of Nervous System Diseases , Xuzhou Medical University , Xuzhou , China."}], "LastName": "Wang", "ForeName": "Zhen", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "b Institute of Nervous System Diseases , Xuzhou Medical University , Xuzhou , China."}], "LastName": "Xu", "ForeName": "Haoyue", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "b Institute of Nervous System Diseases , Xuzhou Medical University , Xuzhou , China."}], "LastName": "Ye", "ForeName": "Chengkun", "Initials": "C"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "b Institute of Nervous System Diseases , Xuzhou Medical University , Xuzhou , China."}], "LastName": "Pan", "ForeName": "Bomin", "Initials": "B"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "b Institute of Nervous System Diseases , Xuzhou Medical University , Xuzhou , China."}], "LastName": "Zhao", "ForeName": "Zongren", "Initials": "Z"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "d Department of Radiation Oncology , Affiliated Hospital of Xuzhou Medical University , Xuzhou , China."}], "LastName": "Zhang", "ForeName": "Longzhen", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "e Key Laboratory for Biotechnology on Medicinal Plants of Jiangsu Province School of Life Science , Jiangsu Normal University , Xuzhou , China."}], "LastName": "Lu", "ForeName": "Jun", "Initials": "J"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "b Institute of Nervous System Diseases , Xuzhou Medical University , Xuzhou , China."}, {"Identifier": [], "Affiliation": "c Department of Neurosurgery , Affiliated Hospital of Xuzhou Medical University , Xuzhou , China."}, {"Identifier": [], "Affiliation": "f Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy , Cancer Institute, Xuzhou Medical University , Xuzhou , China."}], "LastName": "Mei", "ForeName": "Liu Hong", "Initials": "LH"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "a Nanjing Medical University , Nanjing , China."}, {"Identifier": [], "Affiliation": "b Institute of Nervous System Diseases , Xuzhou Medical University , Xuzhou , China."}, {"Identifier": [], "Affiliation": "c Department of Neurosurgery , Affiliated Hospital of Xuzhou Medical University , Xuzhou , China."}, {"Identifier": [], "Affiliation": "f Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy , Cancer Institute, Xuzhou Medical University , Xuzhou , China."}], "LastName": "Rutong", "ForeName": "Yu", "Initials": "Y"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "England", "MedlineTA": "Drug Deliv", "NlmUniqueID": "9417471", "ISSNLinking": "1071-7544"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Angiopep-2"}, {"RegistryNumber": "0", "NameOfSubstance": "Antineoplastic Agents, Alkylating"}, {"RegistryNumber": "0", "NameOfSubstance": "Peptides"}, {"RegistryNumber": "0", "NameOfSubstance": "Prodrugs"}, {"RegistryNumber": "0", "NameOfSubstance": "Radiation-Sensitizing Agents"}, {"RegistryNumber": "1SIA8062RS", "NameOfSubstance": "Polylactic Acid-Polyglycolic Acid Copolymer"}, {"RegistryNumber": "YF1K15M17Y", "NameOfSubstance": "Temozolomide"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": ["administration & dosage", "chemical synthesis", "metabolism"], "DescriptorName": "Antineoplastic Agents, Alkylating"}, {"QualifierName": [], "DescriptorName": "Cell Line, Tumor"}, {"QualifierName": ["methods"], "DescriptorName": "Combined Modality Therapy"}, {"QualifierName": ["methods"], "DescriptorName": "Drug Delivery Systems"}, {"QualifierName": ["metabolism", "therapy"], "DescriptorName": "Glioma"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": [], "DescriptorName": "Mice"}, {"QualifierName": [], "DescriptorName": "Mice, Inbred ICR"}, {"QualifierName": [], "DescriptorName": "Mice, Nude"}, {"QualifierName": ["administration & dosage", "chemistry", "metabolism"], "DescriptorName": "Nanoparticles"}, {"QualifierName": ["administration & dosage", "chemical synthesis", "metabolism"], "DescriptorName": "Peptides"}, {"QualifierName": ["administration & dosage", "chemical synthesis", "metabolism"], "DescriptorName": "Polylactic Acid-Polyglycolic Acid Copolymer"}, {"QualifierName": ["administration & dosage", "chemistry", "metabolism"], "DescriptorName": "Prodrugs"}, {"QualifierName": ["administration & dosage", "chemical synthesis", "metabolism"], "DescriptorName": "Radiation-Sensitizing Agents"}, {"QualifierName": ["methods"], "DescriptorName": "Radiotherapy"}, {"QualifierName": ["administration & dosage", "chemical synthesis", "metabolism"], "DescriptorName": "Temozolomide"}, {"QualifierName": ["methods"], "DescriptorName": "Xenograft Model Antitumor Assays"}]}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Brunetti J, Pillozzi S, Falciani C, et al. (2015). Tumor-selective peptide-carrier delivery of paclitaxel increases in vivo activity of the drug. Sci Rep 5:17736.", "ArticleIdList": ["PMC4667195", "26626158"]}, {"Citation": "Carlson DJ, Yenice KM, Orton CG (2011). Tumor hypoxia is an important mechanism of radioresistance in hypofractionated radiotherapy and must be considered in the treatment planning process. Med Phys 38:6347\u201350.", "ArticleIdList": ["22149817"]}, {"Citation": "Chan JM, Zhang L, Yuet KP, et al. (2009). PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials 30:1627\u201334.", "ArticleIdList": ["19111339"]}, {"Citation": "Chang SM, Theodosopoulos P, Lamborn K, et al. (2004). Temozolomide in the treatment of recurrent malignant glioma. Cancer 100:605\u201311.", "ArticleIdList": ["14745879"]}, {"Citation": "Chan JM, Rhee JW, Drum CL, et al. (2011). In vivo prevention of arterial restenosis with paclitaxel-encapsulated targeted lipid-polymeric nanoparticles. Proc Natl Acad Sci USA 108:19347\u201352.", "ArticleIdList": ["PMC3228458", "22087004"]}, {"Citation": "Cyb AF, Chmelevskaja ZI, Kudrjavceva GT (1985). Clinical experiences with the use of metronidazole in the radiotherapy of cancer patients. Radiobiol Radiother 26:339\u201342.", "ArticleIdList": ["4059519"]}, {"Citation": "Edwards DI. (1993). Nitroimidazole drugs\u2013action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 31:9\u201320.", "ArticleIdList": ["8444678"]}, {"Citation": "Eyre HJ, Ohlsen JD, Frank J, et al. (1984). Randomized trial of radiotherapy versus radiotherapy plus metronidazole for the treatment metastatic cancer to brain. A Southwest Oncology Group study. J Neuro-Oncol 2:325\u201330.", "ArticleIdList": ["6397578"]}, {"Citation": "Friedman HS, Kerby T, Calvert H (2000). Temozolomide and treatment of malignant glioma. Clin Cancer Res 6:2585\u201397.", "ArticleIdList": ["10914698"]}, {"Citation": "Frytak S, Moertel CH, Childs DS (1978). Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 88:361\u20132.", "ArticleIdList": ["629500"]}, {"Citation": "Gondi V, Mehta MP (2015). Dose escalation for GBM in the temozolamide era: in regard to Badiyan et\u00a0al. Int J Radiat Oncol Biol Phys 91:453\u20134.", "ArticleIdList": ["25636772"]}, {"Citation": "Irwin C, Hunn M, Purdie G, Hamilton D (2007). Delay in radiotherapy shortens survival in patients with high grade glioma. J Neuro-Oncol 85:339\u201343.", "ArticleIdList": ["17579810"]}, {"Citation": "Kinner A, Wu W, Staudt C, Iliakis G (2008). Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res 36:5678\u201394.", "ArticleIdList": ["PMC2553572", "18772227"]}, {"Citation": "Komotar RJ, Otten ML, Moise G, Connolly ES (2008). Jr. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma-a critical review. Clin Med Oncol 2:421\u20132.", "ArticleIdList": ["PMC3161656", "21892310"]}, {"Citation": "Kunjachan S, Detappe A, Kumar R, et al. (2015). Nanoparticle mediated tumor vascular disruption: a novel strategy in radiation therapy. Nano Lett 15:7488\u201396.", "ArticleIdList": ["PMC5507193", "26418302"]}, {"Citation": "Lee SH, Mok H, Lee Y, Park TG (2011). Self-assembled siRNA-PLGA conjugate micelles for gene silencing. J Control Release 152:152\u20138.", "ArticleIdList": ["21185893"]}, {"Citation": "Lee JH, Jung TY, Jung S, et al. (2013). Performance status during and after radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma multiforme. J Clin Neurosci 20:503\u20138.", "ArticleIdList": ["23313530"]}, {"Citation": "Li Y, Baiyang L, Leran B, et al. (2017). Reduction-responsive PEtOz-SS-PCL micelle with tailored size to overcome blood-brain barrier and enhance doxorubicin antiglioma effect. Drug Deliv 24:1782\u201390.", "ArticleIdList": ["PMC8241033", "29172749"]}, {"Citation": "Liu R, Colby AH, Gilmore D, et al. (2016). Nanoparticle tumor localization, disruption of autophagosomal trafficking, and prolonged drug delivery improve survival in peritoneal mesothelioma. Biomaterials 102:175\u201386.", "ArticleIdList": ["PMC4948582", "27343465"]}, {"Citation": "Liu H, Li Y, Mozhi A, et al. (2014). SiRNA-phospholipid conjugates for gene and drug delivery in cancer treatment. Biomaterials 35:6519\u201333.", "ArticleIdList": ["24797882"]}, {"Citation": "Liu HM, Zhang YF, Xie YD, et al. (2017). Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy. Int J Nanomed 12:1065\u201383.", "ArticleIdList": ["PMC5308568", "28223799"]}, {"Citation": "Mariotti LG, Pirovano G, Savage KI, et al. (2013). Use of the gamma-H2AX assay to investigate DNA repair dynamics following multiple radiation exposures. PLoS One 8:e79541.", "ArticleIdList": ["PMC3843657", "24312182"]}, {"Citation": "Mason WP, Cairncross JG (2005). Drug Insight: temozolomide as a treatment for malignant glioma\u2013impact of a recent trial. Nat Rev Neurol 1:88\u201395.", "ArticleIdList": ["16932504"]}, {"Citation": "Minniti G, De Sanctis V, Muni R, et al. (2008). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 88:97\u2013103.", "ArticleIdList": ["18250965"]}, {"Citation": "Minniti G, Lanzetta G, Scaringi C, et al. (2012). Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys 83:93\u20139.", "ArticleIdList": ["22079725"]}, {"Citation": "Saleem A, Brown GD, Brady F, et al. (2003). Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 63:2409\u201315.", "ArticleIdList": ["12750260"]}, {"Citation": "Stupp R, Mason WP, van den Bent MJ, et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u201396.", "ArticleIdList": ["15758009"]}, {"Citation": "Stylianopoulos T. (2013). EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther Deliv 4:421\u20133.", "ArticleIdList": ["23557281"]}, {"Citation": "Sukhdeo K, Hambardzumyan D, Rich JN (2011). Glioma development: where did it all go wrong?. Cell 146:187\u20138.", "ArticleIdList": ["21784240"]}, {"Citation": "Thoms J, Bristow RG (2010). DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol 20:217\u201322.", "ArticleIdList": ["20832013"]}, {"Citation": "Urtasun R, Band P, Chapman JD, et al. (1976). Radiation and high-dose metronidazole in supratentorial glioblastomas. N Engl J Med 294:1364\u20137.", "ArticleIdList": ["177873"]}, {"Citation": "Urtasun RC, Miller JD, Frunchak V, et al. (1977). Radiotherapy pilot trials with sensitizers of hypoxic cells: metronidazole in supratentorial glioblastomas. Br J Radiol 50:602\u20133.", "ArticleIdList": ["890240"]}, {"Citation": "Urtasun RC, Sturmwind J, Rabin H, et al. (1974). Letter: \u201cHigh-dose\u201d metronidazole: a preliminary pharmacological study prior to its investigational use in clinical radiotherapy trials. Br J Radiol 47:297\u20139.", "ArticleIdList": ["4830160"]}, {"Citation": "Villano JL, Letarte N, Yu JM, et al. (2012). Hematologic adverse events associated with temozolomide. Cancer Chemother Pharmacol 69:107\u201313.", "ArticleIdList": ["21614470"]}, {"Citation": "Voronina SS, Pelevina II (1977). Increasing the effectiveness of tumor radiotherapy with metronidazole. Med Radiol (Mosk) 22:37\u201343.", "ArticleIdList": ["881955"]}, {"Citation": "Yao H, Qiu H, Shao Z, et al. (2016). Nanoparticle formulation of small DNA molecules, Dbait, improves the sensitivity of hormone-independent prostate cancer to radiotherapy. Nanomed nanotechnol Biol Med 12:2261\u201371.", "ArticleIdList": ["27389144"]}, {"Citation": "Zhang L, Chan JM, Gu FX, et al. (2008). Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano 2:1696\u2013702.", "ArticleIdList": ["PMC4477795", "19206374"]}, {"Citation": "Zhang J, He Y, Shen X, et al. (2016). gamma-H2AX responds to DNA damage induced by long-term exposure to combined low-dose-rate neutron and gamma-ray radiation. Mutat Res Genet Toxicol Environmen Mutagen 795:36\u201340.", "ArticleIdList": ["26774665"]}, {"Citation": "Zhou J, Schmid T, Schnitzer S, Br\u00fcne B (2006). Tumor hypoxia and cancer progression. Cancer Lett 237:10\u201321.", "ArticleIdList": ["16002209"]}]}], "History": [{"Year": "2019", "Month": "2", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "2", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "5", "Day": "11", "Hour": "6", "Minute": "0"}, {"Year": "2019", "Month": "2", "Day": "11"}], "PublicationStatus": "ppublish", "ArticleIdList": ["30744436", "PMC6394306", "10.1080/10717544.2018.1534897"]}}]}